Let’s talk about statins. They are one of the most widely prescribed medications in America. In fact, Atorvastatin was the number one medication prescribed in 2022.¹ Why? Statins not only decrease cholesterol levels but they also reduce the likelihood of experiencing heart attacks and strokes.²
Statins are generally well tolerated. However, a frequent complaint associated with statins is muscle aches or weakness.² Approximately 29% of patients report experiencing this issue.² Many variables contribute to the occurrence of this unwanted adverse effect, including genetic factors.
The genetic aspect that has undergone the most comprehensive research and is linked to a heightened likelihood of myopathy development is the SLCO1B1 gene. The SLCO1B1 gene encodes for a protein that transports statins into liver cells where they are processed and eliminated from the body. Genetic variations in the SLCO1B1 can lead to decreased uptake of statins into the liver, causing higher blood concentrations of the statin, and an increased risk of adverse effects on the muscle.
Other genes that influence your response to statins include CYP3A4 and ABCG2. A comprehensive pharmacogenomic panel will include all these genetic variations.
Understanding your unique genetic makeup can provide valuable insight for providers when selecting an appropriate statin and statin dose. This will mitigate the risk of side effects and reduce “trial and error” prescribing.
As always, consult your provider before making any medication changes.
Ready to optimize your statin treatment for better health? Schedule your initial consultation today!
Sources:
1. "Top 20 outpatient prescription medications", Definitive Healthcare, December 30, 2022, https://www.definitivehc.com/resources/healthcare-insights/top-outpatient-prescription-medications
2. "The Scoop on Statins: What Do You Need to Know?", Million Hearts, December 2018, https://millionhearts.hhs.gov/files/Scoop_on_Statins-508.pdf
3. Anderson, et al. (2015). Pharmacogenomics Applications to Patient Care (3rd ed., pp. 102-114). American College of Clinical Pharmacology.
Comments